Literature DB >> 10882691

Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation.

K Yanagihara1, K Tomono, T Sawai, M Kuroki, Y Kaneko, H Ohno, Y Higashiyama, Y Miyazaki, Y Hirakata, S Maesaki, J Kadota, T Tashiro, S Kohno.   

Abstract

There had been no reports of investigations into biofilms in chronic respiratory infection in vivo. Recently, we established a new murine model of chronic respiratory infection with Pseudomonas aeruginosa. In the present study, we examined the bacteriological effect of combined clarithromycin and levofloxacin against chronic respiratory infection with P. aeruginosa. Scanning electron micrograph of the surface of the catheter intubated in mouse bronchus for 7 days demonstrated in vivo formation of a biofilm containing blood cells, complex fibrous structures and bacteria. Treatment with either clarithromycin alone or levofloxacin alone had no statistical effect on the number of viable bacteria in lung. The combined use of both drugs resulted in a significant decrease in the number of viable bacteria. The present experiment demonstrates that the newly established murine model was useful to investigate the treatment of biofilm-associated chronic respiratory infection with P. aeruginosa, and combination therapy with clarithromycin and levofloxacin was effective in biofilm-associated chronic respiratory infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882691     DOI: 10.1093/jac/46.1.69

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Staphylococcus aureus serves as an iron source for Pseudomonas aeruginosa during in vivo coculture.

Authors:  Lauren M Mashburn; Amy M Jett; Darrin R Akins; Marvin Whiteley
Journal:  J Bacteriol       Date:  2005-01       Impact factor: 3.490

2.  N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa.

Authors:  Tiemei Zhao; Youning Liu
Journal:  BMC Microbiol       Date:  2010-05-12       Impact factor: 3.605

3.  Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice.

Authors:  Wan C Tsai; Marc B Hershenson; Ying Zhou; Umadevi Sajjan
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

4.  Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa.

Authors:  Julia Gödeke; Christian Pustelny; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

5.  Catheter-associated urinary tract infection by Pseudomonas aeruginosa is mediated by exopolysaccharide-independent biofilms.

Authors:  Stephanie J Cole; Angela R Records; Mona W Orr; Sara B Linden; Vincent T Lee
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

6.  Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model.

Authors:  Towako Nagata; Hiroshi Mukae; Junichi Kadota; Tomayoshi Hayashi; Takeshi Fujii; Misuzu Kuroki; Ryo Shirai; Katsunori Yanagihara; Kazunori Tomono; Takehiko Koji; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

7.  Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.

Authors:  Evangelos J Giamarellos-Bourboulis; Theodoros Adamis; George Laoutaris; Lambros Sabracos; Vassilios Koussoulas; Maria Mouktaroudi; Despina Perrea; Panayotis E Karayannacos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 8.  From in vitro to in vivo Models of Bacterial Biofilm-Related Infections.

Authors:  David Lebeaux; Ashwini Chauhan; Olaya Rendueles; Christophe Beloin
Journal:  Pathogens       Date:  2013-05-13

9.  Quinic acid: a potential antibiofilm agent against clinical resistant Pseudomonas aeruginosa.

Authors:  Lan Lu; Yuting Zhao; Guojuan Yi; Mingxing Li; Li Liao; Chen Yang; Chihin Cho; Bin Zhang; Jie Zhu; Kun Zou; Qiang Cheng
Journal:  Chin Med       Date:  2021-08-06       Impact factor: 5.455

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.